Aikaterini Thanou, Tauseef Ali, Omar Haq, Sindhu Kaitha, Jordan Morton, Stavros Stavrakis, Mary Beth Humphrey
{"title":"炎性肠病退伍军人糖皮质激素所致骨质疏松预防措施的应用","authors":"Aikaterini Thanou, Tauseef Ali, Omar Haq, Sindhu Kaitha, Jordan Morton, Stavros Stavrakis, Mary Beth Humphrey","doi":"10.1155/2013/862312","DOIUrl":null,"url":null,"abstract":"<p><p>Purpose. We examined current osteoporosis prevention practices in patients with inflammatory bowel disease (IBD) on chronic steroid using the 2003 American Gastroenterological Association guidelines as standard of care. Methods. We identified all IBD patients followed at the Oklahoma City VA Medical Center from January 2003 to December 2010, who had been on daily oral steroids (prednisone ≥5 mg or budesonide ≥6 mg) for ≥3 consecutive months. Associations of calcium and vitamin D (vitD) prescribing and bone mineral density (BMD) testing with patient characteristics were examined by logistic regression. Results. Sixty-three of 384 consecutive patients met inclusion criteria. Among 86 steroid courses, calcium and vitD were concurrently prescribed in 46%, and BMD was tested in 30%. There was no association of demographic and clinical characteristics with calcium/vitD prescribing and BMD testing. By multivariate analysis, steroid initiation after 2006, compared to before 2006, was associated with a significant increase in calcium (OR = 3.17 and P = 0.02) and vitD (OR = 2.96 and P = 0.02) prescribing and BMD testing (OR = 4.63 and P = 0.004). Conclusions. We observed a low, yet increasing, adherence to osteoporosis prevention guidelines in IBD since 2003, which highlights the need for continued physician education to enhance guideline awareness and implementation.</p>","PeriodicalId":89397,"journal":{"name":"ISRN gastroenterology","volume":"2013 ","pages":"862312"},"PeriodicalIF":0.0000,"publicationDate":"2013-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/862312","citationCount":"9","resultStr":"{\"title\":\"Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease.\",\"authors\":\"Aikaterini Thanou, Tauseef Ali, Omar Haq, Sindhu Kaitha, Jordan Morton, Stavros Stavrakis, Mary Beth Humphrey\",\"doi\":\"10.1155/2013/862312\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Purpose. We examined current osteoporosis prevention practices in patients with inflammatory bowel disease (IBD) on chronic steroid using the 2003 American Gastroenterological Association guidelines as standard of care. Methods. We identified all IBD patients followed at the Oklahoma City VA Medical Center from January 2003 to December 2010, who had been on daily oral steroids (prednisone ≥5 mg or budesonide ≥6 mg) for ≥3 consecutive months. Associations of calcium and vitamin D (vitD) prescribing and bone mineral density (BMD) testing with patient characteristics were examined by logistic regression. Results. Sixty-three of 384 consecutive patients met inclusion criteria. Among 86 steroid courses, calcium and vitD were concurrently prescribed in 46%, and BMD was tested in 30%. There was no association of demographic and clinical characteristics with calcium/vitD prescribing and BMD testing. By multivariate analysis, steroid initiation after 2006, compared to before 2006, was associated with a significant increase in calcium (OR = 3.17 and P = 0.02) and vitD (OR = 2.96 and P = 0.02) prescribing and BMD testing (OR = 4.63 and P = 0.004). Conclusions. We observed a low, yet increasing, adherence to osteoporosis prevention guidelines in IBD since 2003, which highlights the need for continued physician education to enhance guideline awareness and implementation.</p>\",\"PeriodicalId\":89397,\"journal\":{\"name\":\"ISRN gastroenterology\",\"volume\":\"2013 \",\"pages\":\"862312\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2013/862312\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ISRN gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2013/862312\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2013/1/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/862312","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9
摘要
目的。我们以2003年美国胃肠病学协会指南为标准,研究了目前炎症性肠病(IBD)患者使用慢性类固醇预防骨质疏松症的做法。方法。我们确定了2003年1月至2010年12月在俄克拉荷马城退伍军人医疗中心随访的所有IBD患者,这些患者每天口服类固醇(泼尼松≥5mg或布地奈德≥6mg)连续≥3个月。通过逻辑回归检验钙和维生素D (vitD)处方和骨密度(BMD)测试与患者特征的关系。结果。384例连续患者中有63例符合纳入标准。在86个类固醇疗程中,同时服用钙和维生素d的占46%,检测骨密度的占30%。人口学和临床特征与钙/维生素d处方和骨密度测试没有关联。通过多因素分析,与2006年之前相比,2006年之后开始使用类固醇与钙(OR = 3.17, P = 0.02)和维生素d (OR = 2.96, P = 0.02)处方和骨密度测试(OR = 4.63, P = 0.004)的显著增加相关。结论。我们观察到,自2003年以来,IBD患者对骨质疏松预防指南的依从性较低,但仍在增加,这突出了继续对医生进行教育以提高指南意识和实施的必要性。
Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease.
Purpose. We examined current osteoporosis prevention practices in patients with inflammatory bowel disease (IBD) on chronic steroid using the 2003 American Gastroenterological Association guidelines as standard of care. Methods. We identified all IBD patients followed at the Oklahoma City VA Medical Center from January 2003 to December 2010, who had been on daily oral steroids (prednisone ≥5 mg or budesonide ≥6 mg) for ≥3 consecutive months. Associations of calcium and vitamin D (vitD) prescribing and bone mineral density (BMD) testing with patient characteristics were examined by logistic regression. Results. Sixty-three of 384 consecutive patients met inclusion criteria. Among 86 steroid courses, calcium and vitD were concurrently prescribed in 46%, and BMD was tested in 30%. There was no association of demographic and clinical characteristics with calcium/vitD prescribing and BMD testing. By multivariate analysis, steroid initiation after 2006, compared to before 2006, was associated with a significant increase in calcium (OR = 3.17 and P = 0.02) and vitD (OR = 2.96 and P = 0.02) prescribing and BMD testing (OR = 4.63 and P = 0.004). Conclusions. We observed a low, yet increasing, adherence to osteoporosis prevention guidelines in IBD since 2003, which highlights the need for continued physician education to enhance guideline awareness and implementation.